Specific Antiviral Drugs for COVID-19 Market, Global Outlook and Forecast 2022-2028

March 2022 | 100 pages | ID: S35CEE4D68F7EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Specific Antiviral Drugs for COVID-19 in Global, including the following market information:

Global Specific Antiviral Drugs for COVID-19 Market Size 2023-2028, ($ millions)

The global Specific Antiviral Drugs for COVID-19 market is projected to reach US$ million by 2028.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Specific Antiviral Drugs for COVID-19 companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Specific Antiviral Drugs for COVID-19 Market, by Type, 2023-2028 ($ millions)

Global Specific Antiviral Drugs for COVID-19 Market Segment Percentages, by Type

• Tablet
• Injection

Global Specific Antiviral Drugs for COVID-19 Market, by Application, 2023-2028 ($ millions)

Global Specific Antiviral Drugs for COVID-19 Market Segment Percentages, by Application

• Mild Symptom Patient
• Critically Ill Patient

Global Specific Antiviral Drugs for COVID-19 Market, By Region and Country, 2023-2028 ($ Millions)

Global Specific Antiviral Drugs for COVID-19 Market Segment Percentages, By Region and Country

• United States
• Europe
• Asia
• China
• Rest of World

Competitor Analysis

The report also provides analysis of leading market participants including:

Further, the report presents profiles of competitors in the market, key players include:

• Sanofi
• Novartis
• Shanghai Zhongxisanwei
• Teva
• Zydus Cadila
• Mylan
• Apotex
• Advanz Pharma
• Sun Pharma
• Kyung Poong
• Ipca Laboratories
• Hanlim Pharmaceutical
• Bristol Laboratories
• Bayer
• Rising Pharmaceutical
• Shanghai Pharma
• Sichuan Sunny Hope
• Guangzhou Baiyunshan Guanghua Pharmaceutical
• CSPC Group
• KPC Group
• Jinghua Pharmaceutical Group
• Zhongsheng Pharma
• North China Pharmaceutical Group

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Specific Antiviral Drugs for COVID-19 Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Specific Antiviral Drugs for COVID-19 Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 OVERALL MARKET SIZE

2.1 Global Specific Antiviral Drugs for COVID-19 Market Size: 2022 VS 2028
2.2 Global Specific Antiviral Drugs for COVID-19 Market Size, Prospects & Forecasts: 2022-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Key Specific Antiviral Drugs for COVID-19 Players in Global Market
3.2 Global Companies Specific Antiviral Drugs for COVID-19 Product & Technology

4 PLAYERS PROFILES

4.1 Sanofi
  4.1.1 Sanofi Corporate Summary
  4.1.2 Sanofi Business Overview
  4.1.3 Sanofi Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.1.4 Sanofi Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.2 Novartis
  4.2.1 Novartis Corporate Summary
  4.2.2 Novartis Business Overview
  4.2.3 Novartis Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.2.4 Novartis Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.3 Shanghai Zhongxisanwei
  4.3.1 Shanghai Zhongxisanwei Corporate Summary
  4.3.2 Shanghai Zhongxisanwei Business Overview
  4.3.3 Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.3.4 Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.4 Teva
  4.4.1 Teva Corporate Summary
  4.4.2 Teva Business Overview
  4.4.3 Teva Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.4.4 Teva Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.5 Zydus Cadila
  4.5.1 Zydus Cadila Corporate Summary
  4.5.2 Zydus Cadila Business Overview
  4.5.3 Zydus Cadila Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.5.4 Zydus Cadila Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.6 Mylan
  4.6.1 Mylan Corporate Summary
  4.6.2 Mylan Business Overview
  4.6.3 Mylan Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.6.4 Mylan Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.7 Apotex
  4.7.1 Apotex Corporate Summary
  4.7.2 Apotex Business Overview
  4.7.3 Apotex Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.7.4 Apotex Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.8 Advanz Pharma
  4.8.1 Advanz Pharma Corporate Summary
  4.8.2 Advanz Pharma Business Overview
  4.8.3 Advanz Pharma Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.8.4 Advanz Pharma Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.9 Sun Pharma
  4.9.1 Sun Pharma Corporate Summary
  4.9.2 Sun Pharma Business Overview
  4.9.3 Sun Pharma Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.9.4 Sun Pharma Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.10 Kyung Poong
  4.10.1 Kyung Poong Corporate Summary
  4.10.2 Kyung Poong Business Overview
  4.10.3 Kyung Poong Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.10.4 Kyung Poong Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.11 Ipca Laboratories
  4.11.1 Ipca Laboratories Corporate Summary
  4.11.2 Ipca Laboratories Business Overview
  4.11.3 Ipca Laboratories Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.11.4 Ipca Laboratories Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.12 Hanlim Pharmaceutical
  4.12.1 Hanlim Pharmaceutical Corporate Summary
  4.12.2 Hanlim Pharmaceutical Business Overview
  4.12.3 Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.12.4 Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.13 Bristol Laboratories
  4.13.1 Bristol Laboratories Corporate Summary
  4.13.2 Bristol Laboratories Business Overview
  4.13.3 Bristol Laboratories Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.13.4 Bristol Laboratories Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.14 Bayer
  4.14.1 Bayer Corporate Summary
  4.14.2 Bayer Business Overview
  4.14.3 Bayer Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.14.4 Bayer Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.15 Rising Pharmaceutical
  4.15.1 Rising Pharmaceutical Corporate Summary
  4.15.2 Rising Pharmaceutical Business Overview
  4.15.3 Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.15.4 Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.16 Shanghai Pharma
  4.16.1 Shanghai Pharma Corporate Summary
  4.16.2 Shanghai Pharma Business Overview
  4.16.3 Shanghai Pharma Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.16.4 Shanghai Pharma Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.17 Sichuan Sunny Hope
  4.17.1 Sichuan Sunny Hope Corporate Summary
  4.17.2 Sichuan Sunny Hope Business Overview
  4.17.3 Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.17.4 Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.18 Guangzhou Baiyunshan Guanghua Pharmaceutical
  4.18.1 Guangzhou Baiyunshan Guanghua Pharmaceutical Corporate Summary
  4.18.2 Guangzhou Baiyunshan Guanghua Pharmaceutical Business Overview
  4.18.3 Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.18.4 Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.19 CSPC Group
  4.19.1 CSPC Group Corporate Summary
  4.19.2 CSPC Group Business Overview
  4.19.3 CSPC Group Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.19.4 CSPC Group Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.20 KPC Group
  4.20.1 KPC Group Corporate Summary
  4.20.2 KPC Group Business Overview
  4.20.3 KPC Group Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.20.4 KPC Group Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.21 Jinghua Pharmaceutical Group
  4.21.1 Jinghua Pharmaceutical Group Corporate Summary
  4.21.2 Jinghua Pharmaceutical Group Business Overview
  4.21.3 Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.21.4 Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.22 Zhongsheng Pharma
  4.22.1 Zhongsheng Pharma Corporate Summary
  4.22.2 Zhongsheng Pharma Business Overview
  4.22.3 Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.22.4 Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.23 North China Pharmaceutical Group
  4.23.1 North China Pharmaceutical Group Corporate Summary
  4.23.2 North China Pharmaceutical Group Business Overview
  4.23.3 North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
  4.23.4 North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 R&D, and Plans

5 SIGHTS BY REGION

5.1 By Region - Global Specific Antiviral Drugs for COVID-19 Market Size, 2023 & 2028
5.2 By Region - Global Specific Antiviral Drugs for COVID-19 Revenue, (2023-2028)
5.3 United States
  5.3.1 Key Players of Specific Antiviral Drugs for COVID-19 in United States
  5.3.2 United States Specific Antiviral Drugs for COVID-19 Development Current Situation and Forecast
5.4 Europe
  5.4.1 Key Players of Specific Antiviral Drugs for COVID-19 in Europe
  5.4.2 Europe Specific Antiviral Drugs for COVID-19 Development Current Situation and Forecast
5.5 China
  5.5.1 Key Players of Specific Antiviral Drugs for COVID-19 in China
  5.5.2 China Specific Antiviral Drugs for COVID-19 Development Current Situation and Forecast
5.6 Rest of World

6 SIGHTS BY PRODUCT

6.1 by Type - Global Specific Antiviral Drugs for COVID-19 Market Size Markets, 2023 & 2028
6.2 Tablet
6.3 Injection

7 SIGHTS BY APPLICATION

7.1 By Application - Global Specific Antiviral Drugs for COVID-19 Market Size, 2023 & 2028
7.2 Mild Symptom Patient
7.3 Critically Ill Patient

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Specific Antiviral Drugs for COVID-19 Market Opportunities & Trends in Global Market
Table 2. Specific Antiviral Drugs for COVID-19 Market Drivers in Global Market
Table 3. Specific Antiviral Drugs for COVID-19 Market Restraints in Global Market
Table 4. Key Players of Specific Antiviral Drugs for COVID-19 in Global Market
Table 5. Global Companies Specific Antiviral Drugs for COVID-19 Product & Technology
Table 6. Sanofi Corporate Summary
Table 7. Sanofi Specific Antiviral Drugs for COVID-19 Product Offerings
Table 8. Novartis Corporate Summary
Table 9. Novartis Specific Antiviral Drugs for COVID-19 Product Offerings
Table 10. Shanghai Zhongxisanwei Corporate Summary
Table 11. Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Product Offerings
Table 12. Teva Corporate Summary
Table 13. Teva Specific Antiviral Drugs for COVID-19 Product Offerings
Table 14. Zydus Cadila Corporate Summary
Table 15. Zydus Cadila Specific Antiviral Drugs for COVID-19 Product Offerings
Table 16. Mylan Corporate Summary
Table 17. Mylan Specific Antiviral Drugs for COVID-19 Product Offerings
Table 18. Apotex Corporate Summary
Table 19. Apotex Specific Antiviral Drugs for COVID-19 Product Offerings
Table 20. Advanz Pharma Corporate Summary
Table 21. Advanz Pharma Specific Antiviral Drugs for COVID-19 Product Offerings
Table 22. Sun Pharma Corporate Summary
Table 23. Sun Pharma Specific Antiviral Drugs for COVID-19 Product Offerings
Table 24. Kyung Poong Corporate Summary
Table 25. Kyung Poong Specific Antiviral Drugs for COVID-19 Product Offerings
Table 26. Ipca Laboratories Corporate Summary
Table 27. Ipca Laboratories Specific Antiviral Drugs for COVID-19 Product Offerings
Table 28. Hanlim Pharmaceutical Corporate Summary
Table 29. Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Product Offerings
Table 30. Bristol Laboratories Corporate Summary
Table 31. Bristol Laboratories Specific Antiviral Drugs for COVID-19 Product Offerings
Table 32. Bayer Corporate Summary
Table 33. Bayer Specific Antiviral Drugs for COVID-19 Product Offerings
Table 34. Rising Pharmaceutical Corporate Summary
Table 35. Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Product Offerings
Table 36. Shanghai Pharma Corporate Summary
Table 37. Shanghai Pharma Specific Antiviral Drugs for COVID-19 Product Offerings
Table 38. Sichuan Sunny Hope Corporate Summary
Table 39. Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Product Offerings
Table 40. Guangzhou Baiyunshan Guanghua Pharmaceutical Corporate Summary
Table 41. Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Product Offerings
Table 42. CSPC Group Corporate Summary
Table 43. CSPC Group Specific Antiviral Drugs for COVID-19 Product Offerings
Table 44. KPC Group Corporate Summary
Table 45. KPC Group Specific Antiviral Drugs for COVID-19 Product Offerings
Table 46. Jinghua Pharmaceutical Group Corporate Summary
Table 47. Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Product Offerings
Table 48. Zhongsheng Pharma Corporate Summary
Table 49. Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Product Offerings
Table 50. North China Pharmaceutical Group Corporate Summary
Table 51. North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Product Offerings
Table 52. By Region– Global Specific Antiviral Drugs for COVID-19 Revenue, (US$, Mn), 2023 & 2028
Table 53. By Region - Global Specific Antiviral Drugs for COVID-19 Revenue, (US$, Mn), 2023-2028
Table 54. By Type – Global Specific Antiviral Drugs for COVID-19 Market Size, (US$, Mn), 2023 & 2028
Table 55. By Application– Global Specific Antiviral Drugs for COVID-19 Market Size, (US$, Mn), 2023 & 2028

List Of Figures

LIST OF FIGURES

Figure 1. Specific Antiviral Drugs for COVID-19 Segment by Type in 2021
Figure 2. Specific Antiviral Drugs for COVID-19 Segment by Application in 2021
Figure 3. Global Specific Antiviral Drugs for COVID-19 Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Specific Antiviral Drugs for COVID-19 Market Size: 2022 VS 2028 (US$, Mn)
Figure 6. Global Specific Antiviral Drugs for COVID-19 Revenue, 2017-2028 (US$, Mn)
Figure 7. By Region - Global Specific Antiviral Drugs for COVID-19 Revenue Market Share, 2023-2028
Figure 8. By Type - Global Specific Antiviral Drugs for COVID-19 Revenue Market Share, 2023-2028
Figure 9. By Application - Global Specific Antiviral Drugs for COVID-19 Revenue Market Share, 2023-2028